The Global In Situ Hybridization Market Is Experiencing Increased Demand Owing To the Incidence Rate of Cancer All Over the World

 

In Situ Hybridization Market

In situ hybridization (IHT) is a form of DNA hybridization in which the genetic material of an unknown cell is inserted into the living cell without initiating the creation of a new embryo. IHT may be used for the research and development of specific cells but also may be used to insert DNA from an unknown source into a patient's body to develop the potential for disease diagnosis. This process has enabled doctors to successfully use in vitro fertilization (IVF) to successfully treat infertility problems in many patients. It has also enabled scientists to create hair, eye, and tissue samples from live patients in clinical trials for testing drugs and possible treatments. Other uses for in situ hybridization may also include the development of transplants from genetically identical twins, the cloning of animals and insects, and the successful transplant of tissue into a human body that is damaged by disease.

In recent times, there has been an increasing incidence of cancer in the world, which is augmenting the demand in the global In situ hybridization market. For instance, according to the International Agency for Research on Cancer (IARC), there were around 17 million new cases of cancer in 2018 and 9.5 million deaths related to cancer worldwide. The rising cases of cancer. Major studies have been carried out in the last two decades that are related to human diseases and have traced recurrent genomic abnormalities as the main driving factor of cancer in humans. These researches are also fueling the demand in the global In situ hybridization market.

Briefly, in situ hybridization involves the transfer of DNA from an unknown donor into a patient, and then the procedure in which the DNA is inserted into the patient in such a way that it is both active and also placed into a targeted organ or tissue. The donor DNA can come from any source and can be put into the patient at any time depending on the desired location of the implantation. n situ hybridizations occur when the DNA from an unknown donor is inserted into the body of a donor who has cancer cells surgically removed from their body. However, the cost associated with procedures like these can act as a hindering factor restraining the growth of the global In situ hybridization market.

Owing to the increase of cases of cancer in the region, North America is experiencing growing demand in the global In situ hybridization market. For instance, according to the American Cancer Society, in 2020 around 180,6590 cancer cases have been diagnosed in the region, and there were around 606,520 deaths recorded. Apart from these, the U.S. government is also very encouraging towards cancer awareness programs, which is fueling the demand in the global In situ hybridization market. Owing to all these factors, there have been significant industrial developments in the global in-situ hybridization market. For instance, in June 2018, Agilent Technologies Inc. introduced CISH and FISH probes for in-situ hybridization.

Comments

Post a Comment

Popular posts from this blog

The Emergence of COVID-19 to Augment Growth of the Outsourced Drug Discovery Market

Image
  With billions of dollars in research and development costs, pharmaceutical companies around the world are always looking for new ways to address their production processes in a cost-effective manner. One way to achieve this is through outsourcing drug discovery and development services. This type of service refers to the collaboration between small and large biotech and biotechnology companies to conduct research and development activities aimed at finding better solutions to the company's core chemical concerns. Outsourcing of these drug discovery services has enabled established pharmaceutical and biotechnology companies to focus on the development of new products that can bring about significant therapeutic change and provide tangible advantages to the company's shareholders. Contract research organizations manage almost all aspects of drug discovery. Market Dynamics I ncreasing demand for outsourcing analytical testing and clinical trial services, growing R&D ex...
Read more

Otoscope Market Is Gaining Major Traction with Industry Leader Otonexus Medical Technologies Introducing Ultrasound Sensor, Which Aids Middle-Ear Infection Diagnosis

Image
  An otoscope or auricular ear picker is a simple health care tool that is used to inspect the outer ear. Many health care professionals utilize otoscopes to examine ear infections during routine check-ups and to also screen for serious ear disorders. An otoscope possibly provides a more detailed view of the external ear canal and/or ear drum or eardrum. Otoscope or also referred to as auriscope is mainly used to look into eyes. The demand for these medical devices has been on a rise in the recent past. This is typically due to the fact that there is a high burden of ENT-related diseases across the globe. As per the World Health Organization (WHO), by 2050, around 2.5 billion people are estimated to have some degree of hearing loss worldwide. Similarly, there is a heavy burden of sinusitis cases. As per the Sinusitis & Allergy Wellness Center, around 30 million adults in the U.S. are impacted with sinusitis annually. Such a high prevalence of ENT disorders has accelerated the d...
Read more

The Number of Cancer Survivors Is Projected To Increase to 22.2 Million By 2030 Fostering Oncology Drug Pipeline Analysis Market

Image
  North America is estimated to dominate the global oncology drug pipeline analysis market in the near future and this is attributed to the high prevalence of cancer and increasing launch of various novel drugs with improved efficacy. According to the National Cancer Institute, as of January 2019, there were an estimated 16.9 million cancer survivors in the United States. The number of cancer survivors is projected to increase to 22.2 million by 2030. The oncology field is experiencing significant growth and this is attributed to the increasing development of various novel therapies for the treatment of cancer. For instance, in February 2021, Rhizen Pharmaceuticals AG, a clinical-stage, oncology-focused biopharma company, with a 50% stake owned by Alembic Pharmaceuticals and the rest by its Indian CEO Swaroop Vakkalanka, has announced that its the novel, next-generation PI3K-delta inhibitor Umbralisib (Ukoniq) has secured U.S. FDA accelerated approval for the treatment of blood c...
Read more